TLN Thallion Pharmaceuticals

Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) ("Thallion") and LFB
Biotechnologies ("LFB") today announced that they have reached an agreement on
the termination of their Development and Licensing Agreement related to
Thallion's Shigamabs(R) program. All rights to the program will revert back to
Thallion including all data, materials and know-how developed by and for LFB
during the collaboration. LFB will cease to have any rights to the Shigamabs(R)
program and all future quarterly payments due to Thallion by LFB in support of
Shigamabs(R) development will terminate. LFB will pay for all outstanding and
accrued costs related to product manufacturing and Thallion will be responsible
for all remaining costs associated with the completion of the SHIGATEC Phase II
clinical study. 


"Thallion has been an excellent partner in this program and Shigamabs(R) could
be an important product for alleviating the suffering of the thousands of
patients infected by STEC each year," said Guillaume Bologna, executive VP of
LFB Biotechnologies for development & business development. "Despite our strong
collaboration, an internal pipeline prioritization necessitated a reallocation
of our resources. We wish Thallion much success in the future."


"While we are disappointed with the early termination of the LFB collaboration,
we understand LFB's decision to reprioritize their product portfolio in these
challenging economic times. We thank our LFB colleagues for their valuable
contributions to the advancement of the Shigamabs(R) clinical program," said Dr.
Allan Mandelzys, CEO of Thallion. We will now focus on completing the long term
safety evaluation of our patients and close out the SHIGATEC trial in the second
quarter, while initiating efforts towards securing a new development partner for
this asset."


About Shigamabs(R)

Shigamabs(R) consists of two monoclonal antibodies designed to bind specifically
and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga
toxin- producing E. coli bacteria. STEC infections are primarily foodborne
bacterial infections that cause serious health complications, particularly in
young children and the elderly, and affect approximately 314,000 people annually
in the industrialized world. There are no approved products available for the
treatment of STEC infections. The Shigamabs(R) antibodies, administered as a
single intravenous infusion, bind to their respective toxin and neutralize them
by forming a complex that is absorbed and destroyed by the liver and spleen. The
dual antibody approach enables Shigamabs(R) to address STEC infections caused by
E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins.
Shigamabs(R) has obtained orphan drug designation both in the U.S. and in Europe


About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) is a biotechnology company
developing pharmaceutical products in the areas of infectious disease and
oncology. The Company's clinical programs include Shigamabs(R) and TLN-4601, a
novel anti-cancer therapy. Shigamabs(R) is a dual antibody product being
evaluated in a Phase II clinical trial for the treatment of Shiga
toxin-producing E. coli bacterial infections. Additional information about
Thallion can be obtained at www.thallion.com.


About LFB Biotechnologies

LFB Biotechnologies is a subsidiary of LFB Group dedicated to research and
development. LFB is a biopharmaceutical group that develops, manufactures and
markets medicinal products for the treatment of serious and often rare diseases
in several major therapeutic fields, namely Hemostasis, Immunology and Intensive
Care. The LFB Group is the leading manufacturer of plasma-derived medicinal
products in France and 6th worldwide and is also among the leading European
companies for the development of new-generation proteins and treatments based on
biotechnologies. LFB Group's turnover was EUR466 million in 2012. For more
information, visit the LFB website at http://www.lfb.fr/


Forward-Looking Statements

This press release contains certain forward-looking statements, including,
without limitation, statements containing the words "believe", "may", "plan",
"will", "estimate", "continue", "anticipate", "intend", "expect" and other
similar expressions which constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Forward-looking statements
reflect Thallion's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements involve
risks and uncertainties including, but not limited to, risks relating to the
development of the Shigamabs(R) clinical program. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Thallion undertakes no obligation to publicly update
or revise any forward-looking statements either as a result of new information,
future events or otherwise, except as required by applicable Canadian securities
laws.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Michael Singer
Chief Financial Officer
(514) 940-3600
(514) 336-2343 (FAX)
info@thallion.com
www.thallion.com

Thallion Pharmaceuticals (TSXV:TLN)
Historical Stock Chart
From May 2024 to Jun 2024

Thallion Pharmaceuticals (TSXV:TLN)
Historical Stock Chart
From Jun 2023 to Jun 2024